VivoSim Labs' NAMkind™ Data at EUROTOX 2026 Shows Superior Predictive Toxicity for ADCs and Small Molecules — VivoSim Labs, Inc.

Event summary

VivoSim Labs presented new NAMkind™ drug toxicity data at EUROTOX 2026, demonstrating predictive superiority in liver and gastrointestinal safety for small molecules and ADCs.
The NAMkind™ Liver platform successfully ranked trastuzumab deruxtecan as more hepatotoxic than trastuzumab emtansine.
The NAMkind™ Intestine model identified mucosal barrier deterioration before overt tissue cytotoxicity in ADC testing.
VivoSim's extended-culture platforms capture chronic, repeat-dose exposure effects that traditional short-term assays miss.

The big picture

VivoSim Labs' EUROTOX 2026 presentation underscores the growing industry shift towards human-relevant predictive toxicology, driven by regulatory pressures to reduce animal testing. The company's NAMkind™ platform addresses critical safety challenges in ADC development, a rapidly expanding therapeutic area. The broader commercial opportunity lies in helping pharmaceutical developers understand and mitigate toxicity risks before costly clinical trials, potentially saving years of development and millions in potential failures.

What we're watching

Regulatory Tailwinds: The pace at which FDA and other global regulators advance frameworks for New Approach Methodologies will shape demand for VivoSim's predictive toxicology tools.
Market Adoption: Whether pharmaceutical companies will broadly validate and adopt NAMkind™ and VitroSense™ as part of the decision layer between drug discovery and human clinical trials.
Competitive Positioning: How VivoSim's ability to deconvolute complex safety liabilities of next-generation modalities like ADCs will affect its competitive positioning in the predictive toxicology market.